The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.
New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...
After 28 weeks, patients in mazdutide 4mg and 6mg groups demonstrated a mean reduction in HbA1c 1.69% and 1.73% from baseline ...